Optimal cost-effective staging evaluations in prostate cancer

Current Urology Reports

Volumn 8, Issue 3, 2007, Pages 190-196

  Lacy II, Gregory L ^b   Soderdahl, Douglas W ^b   Hernandez, Javier ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN; CAPROMAB PENDETIDE; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

BONE METASTASIS; BONE SCINTISCANNING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HEALTH CARE COST; HUMAN; LAPAROTOMY; LYMPH NODE METASTASIS; METASTASIS; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPHADENECTOMY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SCINTISCANNING; TRANSRECTAL ULTRASONOGRAPHY; BLOOD; COST BENEFIT ANALYSIS; ECHOGRAPHY; ECONOMICS; LYMPHADENECTOMY; MALE; METHODOLOGY; PROGNOSIS; PROSTATE TUMOR; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; DIGITAL RECTAL EXAMINATION; HUMANS; INDICATORS AND REAGENTS; LYMPH NODE EXCISION; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 34248578279     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-007-0005-9     Document Type: Review

References (62)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Saigal CS, Litwin MS: The economic costs of early stage prostate cancer. Pharmacoeconomics 2002, 20:869-878.
3. Paquette EL, Sun L, Paquette LR, et al.: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002, 60:756-759.
4. Chodak GW, Schoenberg HW: Early detection of prostate cancer by routine screening. JAMA 1984, 252:3261-3264.
5. Thompson IM, Ernst JJ, Gangai MP, Spence CR: Adenocarcinoma of the prostate: results of routine urological screening. J Urol 1984, 132:690-692.
6. Farkas A, Schneider D, Perrotti M, et al.: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate specific antigen screening. Urology 1998, 52:444-448; discussion 448-449.
7. Mettlin C, Murphey G, Babian R, et al., investigators of the American Cancer Society National Prostate Cancer Detection Project: The results of a five-year early prostate cancer detection intervention. Cancer 1996, 77:150-159.
8. Jacobsen S, Katusic S, Bergstralh E, et al.: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995, 274:1445-1449.
9. Hernandez J, Thompson I: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004, 101:894-904.
10. Ablin RJ, Soanes WA, Bronson P, et al.: Precipitating antigens of the normal human prostate. J Reprod Fertil 1970, 22:573-574.
11. Ablin RJ, Bronson P, Soanes WA, et al.: Tissue- and species specific antigens of normal human prostatic tissue. J Immunol 1970, 104:1329-1339.
12. Oesterling JE, Chan DW, Epstein JI, et al.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988, 139:766-772.
13. Lange PH, Ercole CJ, Lightner DJ, et al.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989, 141:873-879.
14. Benoit RM, Naslund MJ: Prostate-specific antigen: the best prostatic tumor marker. Urol Clin North Am 1997, 24:451-458.
15. Bill-Axelson A, Holmberg L, Ruutu M, et al.: Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977-1984.
16. Oesterling, JE, Martin SK, Bergstralh EJ, Lowe FC: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993, 269:57-60.
17. Stokkel M, Zwinderman AH, Zwartendijk J, et al.: The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma. Int J Biol Markers 1998, 13:70-76.
18. Partin AW, Mangold LA, Lamm DM, et al.: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001, 58:843-848.
19. D'Amico AV, Wittington R, Malkowicz SB, et al.: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999, 17:168-172.
20. Kattan MW: Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003, 13:111-116.
21. • Cooperberg MR, Broering JM, Latini DM, et al.: Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep 2004, 5:166-172. This paper describes the common practice patterns and trends of physicians in the United States with respect to prostate cancer diagnosis and staging based on data from a large national disease registry.
22. Shinohara K: Improving cancer detection by prostate biopsy: the role of core number and site. Nat Clin Pract Urol 2006, 3:526-527.
23. Salo JO, Kivisaari L, Rannikko S, et al.: Computerized tomography and transrectal ultrasound in the assessment of local extension of prostatic cancer before radical retropubic prostatectomy. J Urol 1987, 137:435-438.
24. Hardeman SW, Causey JQ, Hickey DP, et al.: Transrectal ultrasound for staging prior to radical prostatectomy. Urology 1989, 34:175-180.
25. Rifkin MD, Zerhouni EA, Gatsonis CA, et al.: Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trial. N Engl J Med 1990, 323:621-626.
26. Bates TS, Gillatt DA, Cavanagh PM, et al.: A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation. Br J Urol 1997, 79:927-932.
27. Presti JC Jr, Hricak H, Narayan PA, et al.: Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol 1996, 166:103-108.
28. Smith JA Jr, Scardino PT, Resnick MI, et al.: Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997, 157:902-906.
29. Piatt JF, Bree RL, Schwab RE: The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol 1987, 149:315-318.
30. Engeler CE, Wasserman NF, Zhang G: Preoperative assessment of prostatic carcinoma by computerized tomography: weaknesses and new perspectives. Urology 1992,40:346-350.
31. Purohit RS, Shinohara K, Meng MV, Carroll P: Imaging clinically localized prostate cancer. Urol Clin North Am 2003, 30:279-293.
32. Tarkan T, Turkeri L, Biren T, et al.: The effectiveness of imaging modalities in clinical staging of localized prostate carcinoma. Int Urol Nephrol 1996, 28:773-779.
33. Levran Z, Gonzalez JA, Diokno AC, et al.: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostate cancer? Br J Urol 1985, 75:778-781.
34. Flanigan RC, McKay TC, Olson M, et al.: Limited efficacy of preoperative computed tomography scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology 1996, 48:428-432.
35. Hricak H, Doms GC, Jeffrey RB, et al.: Prostate carcinoma: staging by clinical assessment, CT, and MRI. Radiology 1987, 162:331-336.
36. Huncharek M, Muscat J: Serum prostate specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. J Urol 1997, 158:1870-1874.
37. Lee N, Newhouse JH, Olsson CA, et al.: Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 599 patients. Urology 1999, 54:490-494.
38. Pollack HM, Banner MP: Diagnostic uroradiology. In Clinical Manual of Urology, edn 2. Edited by Hanno PM, Wein AJ. New York: McGraw-Hill; 1994:89-136.
39. Schiebler ML, Schnall MD, Pollack HM, et al.: Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 1993, 189:339-352.
40. Schnall MD, Imai Y, Tomaszewski JE, et al.: Prostate cancer: local staging with endorectal surface coil MR imaging. Radiology 1991, 178:797-802.
41. Rifkin MD, Zerhouni A, Gatsonis CA, et al.: Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trial. N Engl J Med 1990, 323:621-626.
42. Bartolozzi C, Menchi I, Lencioni R, et al.: Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Eur Radiol 1996, 6:339-345.
43. Perrotti M, Kaufman RP Jr, Jennings TA, et al.: Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol 1996, 156:106-109.
44. D'Amico AV, Whittington R, Malkowicz SB, et al.: A multivariate analysis of clinical and pathological factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1994, 30:293-302.
45. D'Amico AV, Whittington R, Malkowicz SB, et al.: Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients. Cancer J Sci Am 1996, 2:343-350.
46. Narayan P, Gajendran V, Taylor SP, et al.: The role of transrectal ultrasound-guided biopsy based staging, preoperative prostate specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995, 46:205-212.
47. Peller PA, Young DC, Marmaduke DP, et al.: Sextant prostate biopsies, histopathologic correlation with radical prostatectomy specimens. Cancer 1995, 75:530-538.
48. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al.: Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994, 44:371-376.
49. Moul JW, Kane CJ, Malkowicz SB: Radical prostatectomy: the role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Cin North Am 2001, 28:459-472.
50. Lange PH: PROSTASCINT scan for staging prostate cancer. Urology 2001, 57:988-993.
51. Manyak MJ, Hinkle GH, Olsen JO, et al.: Immunoscintigraphy with indium-111-capromab pendetide: evaluation before bladder and definitive therapy in patients with prostate cancer. Urology 1999, 54:1058-1063.
52. Murphy GP, Snow PB, Brandt J, et al.: Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans. Prostate 2000, 42:145-149.
53. Polascik TJ, Manyak MJ, Haseman MK, et al.: Comparison of clinical staging algorithms and lllindium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 1999, 85:1586-1592.
54. • Manyak MJ, Javitt M, Kang PS, et al.: The evolution of imaging in advanced prostate cancer. Urol Clin North Am 2006, 33:133-146. This excellent review article references multiple sources and has an in-depth and up-to-date summary of current imaging modalities for staging prostate cancer as well as future tools that are on the horizon.
55. Gerber G, Chodak GW: Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991, 37:418-422.
56. Chybowski FM, Larson-Keller JJ, Bergstrahl EJ, et al.: Predicting radionucleotide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991, 145:313-318.
57. Oesterling JE: Using PSA to eliminate the staging radionuclide bone scan: significant economic implications. Urol Clin North Am 1993, 20:705-711.
58. The American Urological Association Prostate Cancer Clinical Guidelines Panel: Report on the management of clinically localized prostate cancer: clinical practice guidelines. 1995. Available at http://www.auanet.org/ guidelines/main_reports/pca.pdf. Accessed December 29, 2006.
59. Link RE, Morton RA: Radical prostatectomy: indications for pelvic lymphadenectomy in prostate cancer. Urol Clin North Am 2001, 32:491-498.
60. Donohue RE, Mani JH, Whitesel JA, et al.: Intraoperative and early complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. Urology 1990, 35:223-227.
61. Wolfe JS Jr, Shinohara K, Kerlikowske KM, et al.: Selection of patients for laparoscopic pelvic lymphadenectomy prior to radical prostatectomy: a decision analysis. Urology 1993, 42:680-688.
62. O'Dowd GJ, Veltri RW, Orozco R, et al.: Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 1997, 158:687-698.